124 related articles for article (PubMed ID: 7734697)
1. Relationship of epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients.
Koutselini H; Markopoulos C; Lambropoulou S; Gogas H; Kandaraki C; Gogas J
Cytopathology; 1995 Feb; 6(1):14-21. PubMed ID: 7734697
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
5. Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors.
Haerslev T; Jacobsen GK
Virchows Arch; 1994; 424(1):39-46. PubMed ID: 7981902
[TBL] [Abstract][Full Text] [Related]
6. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
[TBL] [Abstract][Full Text] [Related]
7. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
[TBL] [Abstract][Full Text] [Related]
8. The proliferating cell nuclear antigen index in breast carcinomas does not correlate with mitotic index and estrogen receptor immunoreactivity.
Schmitt FC; Pereira EM; Andrade LM; Torresan M; de Lucca L
Pathol Res Pract; 1994 Sep; 190(8):786-91. PubMed ID: 7831155
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical localization of cathepsin D, proliferating cell nuclear antigen and epidermal growth factor receptor in human breast carcinoma analysed by computer image analyser: correlation with histological grade and metastatic behaviour.
Okamura K; Kobayashi I; Matsuo K; Kiyoshima T; Yamamoto K; Miyoshi A; Sakai H
Histopathology; 1997 Dec; 31(6):540-8. PubMed ID: 9447385
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.
Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
J Clin Pathol; 1993 Nov; 46(11):1009-10. PubMed ID: 8254086
[TBL] [Abstract][Full Text] [Related]
11. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
Ruibal A; Garrido-Pumar M; Arias JI
Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
Kolár Z; Murray PG; Zapletalová J
Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
[TBL] [Abstract][Full Text] [Related]
13. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
Gago FE; Tello OM; Diblasi AM; Ciocca DR
J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
15. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score.
Tahan SR; Neuberg DS; Dieffenbach A; Yacoub L
Cancer; 1993 Jun; 71(11):3552-9. PubMed ID: 8098267
[TBL] [Abstract][Full Text] [Related]
16. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
[TBL] [Abstract][Full Text] [Related]
17. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
Keshgegian AA; Cnaan A
Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.
Toi M; Osaki A; Yamada H; Toge T
Eur J Cancer; 1991; 27(8):977-80. PubMed ID: 1832907
[TBL] [Abstract][Full Text] [Related]
19. The expression of products of oncogens c-erbB2 and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female breast.
Jeziorski A; Blonski JZ; Niewiadomska H
J Exp Clin Cancer Res; 2000 Mar; 19(1):61-7. PubMed ID: 10840938
[TBL] [Abstract][Full Text] [Related]
20. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
Moriki T; Takahashi T; Tanioka F; Yamane T; Hara H
Pathol Res Pract; 1995 Nov; 191(11):1122-32. PubMed ID: 8822114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
